nodes	percent_of_prediction	percent_of_DWPC	metapath
Rosiglitazone—SLCO1B1—Methotrexate—bone cancer	0.115	0.438	CbGbCtD
Rosiglitazone—ALB—Methotrexate—bone cancer	0.063	0.24	CbGbCtD
Rosiglitazone—CYP2C9—Cisplatin—bone cancer	0.0523	0.199	CbGbCtD
Rosiglitazone—CYP2D6—Doxorubicin—bone cancer	0.0321	0.122	CbGbCtD
Rosiglitazone—Dofetilide—CYP3A4—bone cancer	0.0133	0.512	CrCbGaD
Rosiglitazone—Pioglitazone—CYP3A4—bone cancer	0.0127	0.488	CrCbGaD
Rosiglitazone—PPARG—periosteum—bone cancer	0.0115	0.175	CbGeAlD
Rosiglitazone—PPARG—leg—bone cancer	0.00914	0.14	CbGeAlD
Rosiglitazone—PPARG—forelimb—bone cancer	0.00907	0.139	CbGeAlD
Rosiglitazone—PPARG—hindlimb—bone cancer	0.00816	0.125	CbGeAlD
Rosiglitazone—Haematocrit decreased—Methotrexate—bone cancer	0.00748	0.0278	CcSEcCtD
Rosiglitazone—PPARG—appendage—bone cancer	0.007	0.107	CbGeAlD
Rosiglitazone—Infection—Carboplatin—bone cancer	0.00613	0.0228	CcSEcCtD
Rosiglitazone—PPARG—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00608	0.0161	CbGpPWpGaD
Rosiglitazone—CYP2A6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00595	0.0158	CbGpPWpGaD
Rosiglitazone—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.00581	0.0154	CbGpPWpGaD
Rosiglitazone—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00578	0.0153	CbGpPWpGaD
Rosiglitazone—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00573	0.0152	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—FOLR1—bone cancer	0.00559	0.0148	CbGpPWpGaD
Rosiglitazone—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00548	0.0145	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00548	0.0145	CbGpPWpGaD
Rosiglitazone—CYP2A6—Xenobiotics—CYP3A4—bone cancer	0.00498	0.0132	CbGpPWpGaD
Rosiglitazone—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00492	0.013	CbGpPWpGaD
Rosiglitazone—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.0049	0.013	CbGpPWpGaD
Rosiglitazone—Fluid retention—Cisplatin—bone cancer	0.00482	0.0179	CcSEcCtD
Rosiglitazone—Multiple fractures—Methotrexate—bone cancer	0.00479	0.0178	CcSEcCtD
Rosiglitazone—Fracture—Methotrexate—bone cancer	0.00479	0.0178	CcSEcCtD
Rosiglitazone—CYP2A6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00479	0.0127	CbGpPWpGaD
Rosiglitazone—ACSL4—connective tissue—bone cancer	0.00444	0.0679	CbGeAlD
Rosiglitazone—Cardiac failure congestive—Cisplatin—bone cancer	0.00406	0.0151	CcSEcCtD
Rosiglitazone—CYP2A6—Fluoropyrimidine Activity—DHFR—bone cancer	0.00394	0.0104	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—TNFRSF11A—bone cancer	0.00387	0.0102	CbGpPWpGaD
Rosiglitazone—Cerebrovascular accident—Cisplatin—bone cancer	0.00376	0.014	CcSEcCtD
Rosiglitazone—Pleural effusion—Methotrexate—bone cancer	0.00364	0.0135	CcSEcCtD
Rosiglitazone—Hyperlipidaemia—Epirubicin—bone cancer	0.00362	0.0135	CcSEcCtD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.00361	0.00957	CbGpPWpGaD
Rosiglitazone—CYP2A6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00342	0.00906	CbGpPWpGaD
Rosiglitazone—Pleural effusion—Epirubicin—bone cancer	0.0034	0.0127	CcSEcCtD
Rosiglitazone—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.0034	0.00901	CbGpPWpGaD
Rosiglitazone—Hyperlipidaemia—Doxorubicin—bone cancer	0.00335	0.0124	CcSEcCtD
Rosiglitazone—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00334	0.00885	CbGpPWpGaD
Rosiglitazone—Nasopharyngitis—Cisplatin—bone cancer	0.00329	0.0123	CcSEcCtD
Rosiglitazone—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.00327	0.00867	CbGpPWpGaD
Rosiglitazone—Pleural effusion—Doxorubicin—bone cancer	0.00315	0.0117	CcSEcCtD
Rosiglitazone—PPARG—Generic Transcription Pathway—ZNF77—bone cancer	0.0031	0.00823	CbGpPWpGaD
Rosiglitazone—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.0031	0.00823	CbGpPWpGaD
Rosiglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0031	0.00821	CbGpPWpGaD
Rosiglitazone—Hyperbilirubinaemia—Methotrexate—bone cancer	0.00306	0.0114	CcSEcCtD
Rosiglitazone—ACSL4—tendon—bone cancer	0.00305	0.0467	CbGeAlD
Rosiglitazone—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00304	0.00805	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.00303	0.00804	CbGpPWpGaD
Rosiglitazone—ACSL4—bone marrow—bone cancer	0.00296	0.0452	CbGeAlD
Rosiglitazone—ACSL4—spinal cord—bone cancer	0.00295	0.045	CbGeAlD
Rosiglitazone—Hepatic enzyme increased—Methotrexate—bone cancer	0.00294	0.011	CcSEcCtD
Rosiglitazone—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.00292	0.00774	CbGpPWpGaD
Rosiglitazone—Hyperbilirubinaemia—Epirubicin—bone cancer	0.00287	0.0107	CcSEcCtD
Rosiglitazone—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00283	0.00749	CbGpPWpGaD
Rosiglitazone—Acute coronary syndrome—Cisplatin—bone cancer	0.0028	0.0104	CcSEcCtD
Rosiglitazone—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.00279	0.0074	CbGpPWpGaD
Rosiglitazone—Myocardial infarction—Cisplatin—bone cancer	0.00278	0.0104	CcSEcCtD
Rosiglitazone—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.00277	0.00734	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00271	0.00718	CbGpPWpGaD
Rosiglitazone—Hepatobiliary disease—Cisplatin—bone cancer	0.00269	0.00999	CcSEcCtD
Rosiglitazone—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.00268	0.00712	CbGpPWpGaD
Rosiglitazone—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.00266	0.00706	CbGpPWpGaD
Rosiglitazone—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.00265	0.00987	CcSEcCtD
Rosiglitazone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00265	0.00702	CbGpPWpGaD
Rosiglitazone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—bone cancer	0.00264	0.00699	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—NDUFA12—bone cancer	0.00262	0.00696	CbGpPWpGaD
Rosiglitazone—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.00257	0.00682	CbGpPWpGaD
Rosiglitazone—Connective tissue disorder—Cisplatin—bone cancer	0.0025	0.00932	CcSEcCtD
Rosiglitazone—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.00249	0.0066	CbGpPWpGaD
Rosiglitazone—Pulmonary oedema—Methotrexate—bone cancer	0.00248	0.00922	CcSEcCtD
Rosiglitazone—Fluid retention—Epirubicin—bone cancer	0.00247	0.0092	CcSEcCtD
Rosiglitazone—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.00247	0.00654	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00246	0.00653	CbGpPWpGaD
Rosiglitazone—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.00243	0.00644	CbGpPWpGaD
Rosiglitazone—Eye disorder—Cisplatin—bone cancer	0.00238	0.00886	CcSEcCtD
Rosiglitazone—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.00238	0.0063	CbGpPWpGaD
Rosiglitazone—Cardiac disorder—Cisplatin—bone cancer	0.00237	0.0088	CcSEcCtD
Rosiglitazone—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.00237	0.00627	CbGpPWpGaD
Rosiglitazone—Diabetes mellitus—Methotrexate—bone cancer	0.00232	0.00865	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Epirubicin—bone cancer	0.00232	0.00863	CcSEcCtD
Rosiglitazone—Immune system disorder—Cisplatin—bone cancer	0.0023	0.00856	CcSEcCtD
Rosiglitazone—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.0023	0.00609	CbGpPWpGaD
Rosiglitazone—Fluid retention—Doxorubicin—bone cancer	0.00229	0.00852	CcSEcCtD
Rosiglitazone—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.00227	0.00603	CbGpPWpGaD
Rosiglitazone—Hepatic failure—Methotrexate—bone cancer	0.00225	0.00837	CcSEcCtD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.00224	0.00593	CbGpPWpGaD
Rosiglitazone—Malnutrition—Cisplatin—bone cancer	0.00222	0.00825	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Epirubicin—bone cancer	0.00218	0.00809	CcSEcCtD
Rosiglitazone—ACSL4—Metabolism—NT5C3A—bone cancer	0.00217	0.00577	CbGpPWpGaD
Rosiglitazone—Hepatic function abnormal—Epirubicin—bone cancer	0.00216	0.00805	CcSEcCtD
Rosiglitazone—Pulmonary oedema—Doxorubicin—bone cancer	0.00215	0.00799	CcSEcCtD
Rosiglitazone—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.00211	0.00559	CbGpPWpGaD
Rosiglitazone—Hepatic failure—Epirubicin—bone cancer	0.00211	0.00783	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Epirubicin—bone cancer	0.00209	0.00776	CcSEcCtD
Rosiglitazone—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00208	0.00552	CbGpPWpGaD
Rosiglitazone—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00207	0.00548	CbGpPWpGaD
Rosiglitazone—Cerebrovascular accident—Methotrexate—bone cancer	0.00206	0.00767	CcSEcCtD
Rosiglitazone—Anaemia—Cisplatin—bone cancer	0.00205	0.00763	CcSEcCtD
Rosiglitazone—CYP2A6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00204	0.00541	CbGpPWpGaD
Rosiglitazone—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.00202	0.00534	CbGpPWpGaD
Rosiglitazone—Increased appetite—Epirubicin—bone cancer	0.00201	0.00749	CcSEcCtD
Rosiglitazone—Diabetes mellitus—Doxorubicin—bone cancer	0.00201	0.00749	CcSEcCtD
Rosiglitazone—Hepatic function abnormal—Doxorubicin—bone cancer	0.002	0.00745	CcSEcCtD
Rosiglitazone—PPARG—connective tissue—bone cancer	0.002	0.0305	CbGeAlD
Rosiglitazone—Leukopenia—Cisplatin—bone cancer	0.00199	0.00739	CcSEcCtD
Rosiglitazone—Hepatic failure—Doxorubicin—bone cancer	0.00195	0.00725	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Epirubicin—bone cancer	0.00194	0.00721	CcSEcCtD
Rosiglitazone—Cardiac failure—Epirubicin—bone cancer	0.00194	0.00721	CcSEcCtD
Rosiglitazone—Cerebrovascular accident—Epirubicin—bone cancer	0.00193	0.00718	CcSEcCtD
Rosiglitazone—Cardiac failure congestive—Doxorubicin—bone cancer	0.00193	0.00718	CcSEcCtD
Rosiglitazone—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.0019	0.00504	CbGpPWpGaD
Rosiglitazone—Myalgia—Cisplatin—bone cancer	0.00189	0.00703	CcSEcCtD
Rosiglitazone—Increased appetite—Doxorubicin—bone cancer	0.00186	0.00693	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Cisplatin—bone cancer	0.00181	0.00674	CcSEcCtD
Rosiglitazone—Oedema—Cisplatin—bone cancer	0.00181	0.00674	CcSEcCtD
Rosiglitazone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00181	0.0048	CbGpPWpGaD
Rosiglitazone—Infection—Cisplatin—bone cancer	0.0018	0.00669	CcSEcCtD
Rosiglitazone—Hypoglycaemia—Doxorubicin—bone cancer	0.00179	0.00667	CcSEcCtD
Rosiglitazone—Cardiac failure—Doxorubicin—bone cancer	0.00179	0.00667	CcSEcCtD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—CDK4—bone cancer	0.00179	0.00475	CbGpPWpGaD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—MET—bone cancer	0.00179	0.00475	CbGpPWpGaD
Rosiglitazone—Cerebrovascular accident—Doxorubicin—bone cancer	0.00179	0.00665	CcSEcCtD
Rosiglitazone—Nervous system disorder—Cisplatin—bone cancer	0.00178	0.00661	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Cisplatin—bone cancer	0.00177	0.0066	CcSEcCtD
Rosiglitazone—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00177	0.0047	CbGpPWpGaD
Rosiglitazone—Nasopharyngitis—Epirubicin—bone cancer	0.00169	0.00629	CcSEcCtD
Rosiglitazone—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.00169	0.00447	CbGpPWpGaD
Rosiglitazone—CYP2A6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00168	0.00444	CbGpPWpGaD
Rosiglitazone—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00165	0.00614	CcSEcCtD
Rosiglitazone—Upper respiratory tract infection—Methotrexate—bone cancer	0.00162	0.00604	CcSEcCtD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—bone cancer	0.0016	0.00424	CbGpPWpGaD
Rosiglitazone—PPARG—Transcriptional regulation of white adipocyte differentiation—CDK4—bone cancer	0.00158	0.0042	CbGpPWpGaD
Rosiglitazone—Nasopharyngitis—Doxorubicin—bone cancer	0.00157	0.00582	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Cisplatin—bone cancer	0.00156	0.00582	CcSEcCtD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—RB1—bone cancer	0.00156	0.00413	CbGpPWpGaD
Rosiglitazone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00155	0.0041	CbGpPWpGaD
Rosiglitazone—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00154	0.00575	CcSEcCtD
Rosiglitazone—ALB—Folate Metabolism—DHFR—bone cancer	0.00154	0.00407	CbGpPWpGaD
Rosiglitazone—Upper respiratory tract infection—Epirubicin—bone cancer	0.00152	0.00565	CcSEcCtD
Rosiglitazone—PPARG—Gene Expression—ZNF77—bone cancer	0.00149	0.00396	CbGpPWpGaD
Rosiglitazone—Weight increased—Epirubicin—bone cancer	0.00149	0.00554	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Epirubicin—bone cancer	0.00148	0.00549	CcSEcCtD
Rosiglitazone—Hepatobiliary disease—Methotrexate—bone cancer	0.00147	0.00548	CcSEcCtD
Rosiglitazone—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00145	0.00538	CcSEcCtD
Rosiglitazone—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.00144	0.00382	CbGpPWpGaD
Rosiglitazone—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00141	0.00374	CbGpPWpGaD
Rosiglitazone—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00141	0.00523	CcSEcCtD
Rosiglitazone—Hepatitis—Methotrexate—bone cancer	0.0014	0.0052	CcSEcCtD
Rosiglitazone—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00139	0.00369	CbGpPWpGaD
Rosiglitazone—Hepatobiliary disease—Epirubicin—bone cancer	0.00138	0.00513	CcSEcCtD
Rosiglitazone—Weight increased—Doxorubicin—bone cancer	0.00138	0.00512	CcSEcCtD
Rosiglitazone—PPARG—tendon—bone cancer	0.00137	0.021	CbGeAlD
Rosiglitazone—Sinusitis—Epirubicin—bone cancer	0.00137	0.00509	CcSEcCtD
Rosiglitazone—Hyperglycaemia—Doxorubicin—bone cancer	0.00136	0.00508	CcSEcCtD
Rosiglitazone—ALB—Platelet degranulation—SPARC—bone cancer	0.00135	0.00357	CbGpPWpGaD
Rosiglitazone—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00134	0.00498	CcSEcCtD
Rosiglitazone—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.00133	0.00354	CbGpPWpGaD
Rosiglitazone—PPARG—bone marrow—bone cancer	0.00133	0.0203	CbGeAlD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—MDM2—bone cancer	0.00133	0.00352	CbGpPWpGaD
Rosiglitazone—Erythema multiforme—Methotrexate—bone cancer	0.00132	0.00492	CcSEcCtD
Rosiglitazone—Hepatitis—Epirubicin—bone cancer	0.00131	0.00487	CcSEcCtD
Rosiglitazone—PPARG—Circadian rythm related genes—GNA11—bone cancer	0.00131	0.00347	CbGpPWpGaD
Rosiglitazone—Eye disorder—Methotrexate—bone cancer	0.00131	0.00486	CcSEcCtD
Rosiglitazone—PPARG—Circadian rythm related genes—EZH2—bone cancer	0.0013	0.00345	CbGpPWpGaD
Rosiglitazone—Asthenia—Cisplatin—bone cancer	0.0013	0.00483	CcSEcCtD
Rosiglitazone—Cardiac disorder—Methotrexate—bone cancer	0.0013	0.00483	CcSEcCtD
Rosiglitazone—Oedema peripheral—Epirubicin—bone cancer	0.00129	0.0048	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Epirubicin—bone cancer	0.00129	0.00478	CcSEcCtD
Rosiglitazone—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.00128	0.0034	CbGpPWpGaD
Rosiglitazone—Hepatobiliary disease—Doxorubicin—bone cancer	0.00128	0.00475	CcSEcCtD
Rosiglitazone—Sinusitis—Doxorubicin—bone cancer	0.00127	0.00471	CcSEcCtD
Rosiglitazone—Immune system disorder—Methotrexate—bone cancer	0.00126	0.0047	CcSEcCtD
Rosiglitazone—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00126	0.00334	CbGpPWpGaD
Rosiglitazone—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00124	0.0033	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Cisplatin—bone cancer	0.00124	0.00461	CcSEcCtD
Rosiglitazone—Erythema multiforme—Epirubicin—bone cancer	0.00124	0.0046	CcSEcCtD
Rosiglitazone—Eye disorder—Epirubicin—bone cancer	0.00122	0.00455	CcSEcCtD
Rosiglitazone—Malnutrition—Methotrexate—bone cancer	0.00122	0.00453	CcSEcCtD
Rosiglitazone—Cardiac disorder—Epirubicin—bone cancer	0.00121	0.00452	CcSEcCtD
Rosiglitazone—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.00121	0.00322	CbGpPWpGaD
Rosiglitazone—Hepatitis—Doxorubicin—bone cancer	0.00121	0.00451	CcSEcCtD
Rosiglitazone—Oedema peripheral—Doxorubicin—bone cancer	0.00119	0.00444	CcSEcCtD
Rosiglitazone—Connective tissue disorder—Doxorubicin—bone cancer	0.00119	0.00443	CcSEcCtD
Rosiglitazone—Immune system disorder—Epirubicin—bone cancer	0.00118	0.0044	CcSEcCtD
Rosiglitazone—Back pain—Methotrexate—bone cancer	0.00118	0.00438	CcSEcCtD
Rosiglitazone—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00116	0.00307	CbGpPWpGaD
Rosiglitazone—PPARG—Regulation of retinoblastoma protein—JUN—bone cancer	0.00116	0.00306	CbGpPWpGaD
Rosiglitazone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00115	0.00305	CbGpPWpGaD
Rosiglitazone—Erythema multiforme—Doxorubicin—bone cancer	0.00115	0.00426	CcSEcCtD
Rosiglitazone—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00114	0.00303	CbGpPWpGaD
Rosiglitazone—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00114	0.00303	CbGpPWpGaD
Rosiglitazone—Rash—Cisplatin—bone cancer	0.00114	0.00425	CcSEcCtD
Rosiglitazone—Dermatitis—Cisplatin—bone cancer	0.00114	0.00424	CcSEcCtD
Rosiglitazone—Malnutrition—Epirubicin—bone cancer	0.00114	0.00424	CcSEcCtD
Rosiglitazone—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.00113	0.00301	CbGpPWpGaD
Rosiglitazone—Eye disorder—Doxorubicin—bone cancer	0.00113	0.00421	CcSEcCtD
Rosiglitazone—Anaemia—Methotrexate—bone cancer	0.00113	0.00419	CcSEcCtD
Rosiglitazone—Cardiac disorder—Doxorubicin—bone cancer	0.00112	0.00418	CcSEcCtD
Rosiglitazone—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.00112	0.00297	CbGpPWpGaD
Rosiglitazone—Back pain—Epirubicin—bone cancer	0.0011	0.0041	CcSEcCtD
Rosiglitazone—Immune system disorder—Doxorubicin—bone cancer	0.00109	0.00407	CcSEcCtD
Rosiglitazone—Leukopenia—Methotrexate—bone cancer	0.00109	0.00405	CcSEcCtD
Rosiglitazone—Nausea—Cisplatin—bone cancer	0.00108	0.004	CcSEcCtD
Rosiglitazone—PTGS1—connective tissue—bone cancer	0.00107	0.0163	CbGeAlD
Rosiglitazone—Malnutrition—Doxorubicin—bone cancer	0.00105	0.00392	CcSEcCtD
Rosiglitazone—Anaemia—Epirubicin—bone cancer	0.00105	0.00392	CcSEcCtD
Rosiglitazone—PPARG—Generic Transcription Pathway—NR1I2—bone cancer	0.00105	0.00279	CbGpPWpGaD
Rosiglitazone—Arthralgia—Methotrexate—bone cancer	0.00104	0.00386	CcSEcCtD
Rosiglitazone—Myalgia—Methotrexate—bone cancer	0.00104	0.00386	CcSEcCtD
Rosiglitazone—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00102	0.00271	CbGpPWpGaD
Rosiglitazone—Leukopenia—Epirubicin—bone cancer	0.00102	0.00379	CcSEcCtD
Rosiglitazone—Back pain—Doxorubicin—bone cancer	0.00102	0.00379	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Methotrexate—bone cancer	0.000994	0.0037	CcSEcCtD
Rosiglitazone—Infection—Methotrexate—bone cancer	0.000987	0.00367	CcSEcCtD
Rosiglitazone—Hypertension—Epirubicin—bone cancer	0.000984	0.00366	CcSEcCtD
Rosiglitazone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000982	0.0026	CbGpPWpGaD
Rosiglitazone—Nervous system disorder—Methotrexate—bone cancer	0.000974	0.00362	CcSEcCtD
Rosiglitazone—Anaemia—Doxorubicin—bone cancer	0.000974	0.00362	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Methotrexate—bone cancer	0.000973	0.00362	CcSEcCtD
Rosiglitazone—Myalgia—Epirubicin—bone cancer	0.00097	0.00361	CcSEcCtD
Rosiglitazone—Arthralgia—Epirubicin—bone cancer	0.00097	0.00361	CcSEcCtD
Rosiglitazone—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000969	0.00257	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—ENO2—bone cancer	0.000953	0.00253	CbGpPWpGaD
Rosiglitazone—Leukopenia—Doxorubicin—bone cancer	0.000944	0.00351	CcSEcCtD
Rosiglitazone—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000941	0.0025	CbGpPWpGaD
Rosiglitazone—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00094	0.00249	CbGpPWpGaD
Rosiglitazone—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000932	0.00247	CbGpPWpGaD
Rosiglitazone—Oedema—Epirubicin—bone cancer	0.00093	0.00346	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Epirubicin—bone cancer	0.00093	0.00346	CcSEcCtD
Rosiglitazone—Infection—Epirubicin—bone cancer	0.000924	0.00344	CcSEcCtD
Rosiglitazone—Nervous system disorder—Epirubicin—bone cancer	0.000912	0.00339	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Epirubicin—bone cancer	0.00091	0.00339	CcSEcCtD
Rosiglitazone—Hypertension—Doxorubicin—bone cancer	0.00091	0.00339	CcSEcCtD
Rosiglitazone—PPARG—Adipogenesis—RB1—bone cancer	0.000906	0.0024	CbGpPWpGaD
Rosiglitazone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000905	0.00337	CcSEcCtD
Rosiglitazone—Arthralgia—Doxorubicin—bone cancer	0.000898	0.00334	CcSEcCtD
Rosiglitazone—Myalgia—Doxorubicin—bone cancer	0.000898	0.00334	CcSEcCtD
Rosiglitazone—CYP2A6—Biological oxidations—CYP3A4—bone cancer	0.00089	0.00236	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—DHFR—bone cancer	0.000884	0.00234	CbGpPWpGaD
Rosiglitazone—CYP2A6—Fluoropyrimidine Activity—TP53—bone cancer	0.000879	0.00233	CbGpPWpGaD
Rosiglitazone—CYP2A6—NRF2 pathway—GSTP1—bone cancer	0.000868	0.0023	CbGpPWpGaD
Rosiglitazone—CYP2A6—NRF2 pathway—TGFBR2—bone cancer	0.000868	0.0023	CbGpPWpGaD
Rosiglitazone—Oedema—Doxorubicin—bone cancer	0.00086	0.0032	CcSEcCtD
Rosiglitazone—Anaphylactic shock—Doxorubicin—bone cancer	0.00086	0.0032	CcSEcCtD
Rosiglitazone—Gastrointestinal disorder—Methotrexate—bone cancer	0.000858	0.00319	CcSEcCtD
Rosiglitazone—Fatigue—Methotrexate—bone cancer	0.000857	0.00319	CcSEcCtD
Rosiglitazone—Infection—Doxorubicin—bone cancer	0.000855	0.00318	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000847	0.00315	CcSEcCtD
Rosiglitazone—Nervous system disorder—Doxorubicin—bone cancer	0.000844	0.00314	CcSEcCtD
Rosiglitazone—Thrombocytopenia—Doxorubicin—bone cancer	0.000842	0.00313	CcSEcCtD
Rosiglitazone—ACSL4—Metabolism—GNA11—bone cancer	0.000826	0.00219	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000811	0.00215	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—NDUFA12—bone cancer	0.000806	0.00214	CbGpPWpGaD
Rosiglitazone—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000805	0.00213	CbGpPWpGaD
Rosiglitazone—Gastrointestinal disorder—Epirubicin—bone cancer	0.000803	0.00299	CcSEcCtD
Rosiglitazone—Fatigue—Epirubicin—bone cancer	0.000802	0.00298	CcSEcCtD
Rosiglitazone—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000796	0.00211	CbGpPWpGaD
Rosiglitazone—Constipation—Epirubicin—bone cancer	0.000795	0.00296	CcSEcCtD
Rosiglitazone—Urticaria—Methotrexate—bone cancer	0.000789	0.00294	CcSEcCtD
Rosiglitazone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000784	0.00292	CcSEcCtD
Rosiglitazone—CYP2A6—Biological oxidations—GSTP1—bone cancer	0.000761	0.00202	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—CYP3A4—bone cancer	0.000749	0.00199	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000745	0.00197	CbGpPWpGaD
Rosiglitazone—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000743	0.00276	CcSEcCtD
Rosiglitazone—Fatigue—Doxorubicin—bone cancer	0.000742	0.00276	CcSEcCtD
Rosiglitazone—Urticaria—Epirubicin—bone cancer	0.000739	0.00275	CcSEcCtD
Rosiglitazone—Constipation—Doxorubicin—bone cancer	0.000736	0.00274	CcSEcCtD
Rosiglitazone—PPARG—Circadian rythm related genes—CDK4—bone cancer	0.000735	0.00195	CbGpPWpGaD
Rosiglitazone—PTGS1—tendon—bone cancer	0.000735	0.0112	CbGeAlD
Rosiglitazone—PPARG—Gene Expression—FUS—bone cancer	0.00073	0.00193	CbGpPWpGaD
Rosiglitazone—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000724	0.00192	CbGpPWpGaD
Rosiglitazone—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000713	0.00189	CbGpPWpGaD
Rosiglitazone—Asthenia—Methotrexate—bone cancer	0.000713	0.00265	CcSEcCtD
Rosiglitazone—PTGS1—spinal cord—bone cancer	0.000708	0.0108	CbGeAlD
Rosiglitazone—Pruritus—Methotrexate—bone cancer	0.000703	0.00262	CcSEcCtD
Rosiglitazone—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.0007	0.00186	CbGpPWpGaD
Rosiglitazone—Urticaria—Doxorubicin—bone cancer	0.000684	0.00254	CcSEcCtD
Rosiglitazone—Diarrhoea—Methotrexate—bone cancer	0.00068	0.00253	CcSEcCtD
Rosiglitazone—PPARG—Metabolism—NT5C3A—bone cancer	0.000667	0.00177	CbGpPWpGaD
Rosiglitazone—Asthenia—Epirubicin—bone cancer	0.000667	0.00248	CcSEcCtD
Rosiglitazone—Pruritus—Epirubicin—bone cancer	0.000658	0.00245	CcSEcCtD
Rosiglitazone—Dizziness—Methotrexate—bone cancer	0.000657	0.00244	CcSEcCtD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000655	0.00174	CbGpPWpGaD
Rosiglitazone—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000646	0.00171	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—GSTP1—bone cancer	0.00064	0.0017	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Epirubicin—bone cancer	0.000636	0.00237	CcSEcCtD
Rosiglitazone—SLCO1B1—Metabolism—NDUFA12—bone cancer	0.000634	0.00168	CbGpPWpGaD
Rosiglitazone—Rash—Methotrexate—bone cancer	0.000627	0.00233	CcSEcCtD
Rosiglitazone—Dermatitis—Methotrexate—bone cancer	0.000626	0.00233	CcSEcCtD
Rosiglitazone—Headache—Methotrexate—bone cancer	0.000622	0.00232	CcSEcCtD
Rosiglitazone—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000618	0.00164	CbGpPWpGaD
Rosiglitazone—Asthenia—Doxorubicin—bone cancer	0.000617	0.0023	CcSEcCtD
Rosiglitazone—Dizziness—Epirubicin—bone cancer	0.000615	0.00229	CcSEcCtD
Rosiglitazone—Pruritus—Doxorubicin—bone cancer	0.000609	0.00226	CcSEcCtD
Rosiglitazone—CYP2C8—Biological oxidations—CYP3A4—bone cancer	0.000608	0.00161	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	0.0006	0.00159	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000597	0.00158	CbGpPWpGaD
Rosiglitazone—Nausea—Methotrexate—bone cancer	0.00059	0.0022	CcSEcCtD
Rosiglitazone—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000589	0.00156	CbGpPWpGaD
Rosiglitazone—Diarrhoea—Doxorubicin—bone cancer	0.000589	0.00219	CcSEcCtD
Rosiglitazone—Rash—Epirubicin—bone cancer	0.000586	0.00218	CcSEcCtD
Rosiglitazone—Dermatitis—Epirubicin—bone cancer	0.000586	0.00218	CcSEcCtD
Rosiglitazone—Headache—Epirubicin—bone cancer	0.000583	0.00217	CcSEcCtD
Rosiglitazone—Dizziness—Doxorubicin—bone cancer	0.000569	0.00212	CcSEcCtD
Rosiglitazone—PTGS1—Metabolism—NDUFA12—bone cancer	0.000564	0.0015	CbGpPWpGaD
Rosiglitazone—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000558	0.00148	CbGpPWpGaD
Rosiglitazone—Nausea—Epirubicin—bone cancer	0.000552	0.00205	CcSEcCtD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000546	0.00145	CbGpPWpGaD
Rosiglitazone—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000543	0.00144	CbGpPWpGaD
Rosiglitazone—Rash—Doxorubicin—bone cancer	0.000542	0.00202	CcSEcCtD
Rosiglitazone—Dermatitis—Doxorubicin—bone cancer	0.000542	0.00202	CcSEcCtD
Rosiglitazone—Headache—Doxorubicin—bone cancer	0.000539	0.00201	CcSEcCtD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000538	0.00143	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000535	0.00142	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—NDUFA12—bone cancer	0.000534	0.00141	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—NT5C3A—bone cancer	0.000526	0.00139	CbGpPWpGaD
Rosiglitazone—CYP2C8—Biological oxidations—GSTP1—bone cancer	0.00052	0.00138	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	0.000513	0.00136	CbGpPWpGaD
Rosiglitazone—Nausea—Doxorubicin—bone cancer	0.000511	0.0019	CcSEcCtD
Rosiglitazone—PPARG—Gene Expression—NR1I2—bone cancer	0.000506	0.00134	CbGpPWpGaD
Rosiglitazone—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000503	0.00133	CbGpPWpGaD
Rosiglitazone—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000499	0.00132	CbGpPWpGaD
Rosiglitazone—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000495	0.00131	CbGpPWpGaD
Rosiglitazone—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000495	0.00131	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000492	0.00131	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000488	0.00129	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000485	0.00129	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—JUN—bone cancer	0.000474	0.00126	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—NT5C3A—bone cancer	0.000468	0.00124	CbGpPWpGaD
Rosiglitazone—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000464	0.00123	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000464	0.00123	CbGpPWpGaD
Rosiglitazone—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	0.000458	0.00121	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.000458	0.00121	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—NT5C3A—bone cancer	0.000442	0.00117	CbGpPWpGaD
Rosiglitazone—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000427	0.00113	CbGpPWpGaD
Rosiglitazone—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000423	0.00112	CbGpPWpGaD
Rosiglitazone—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000423	0.00112	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000421	0.00112	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000417	0.00111	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000417	0.00111	CbGpPWpGaD
Rosiglitazone—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.0004	0.00106	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000382	0.00101	CbGpPWpGaD
Rosiglitazone—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000382	0.00101	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—EIF2S1—bone cancer	0.000374	0.00099	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NDUFA12—bone cancer	0.000364	0.000966	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NDUFA12—bone cancer	0.000362	0.000961	CbGpPWpGaD
Rosiglitazone—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000362	0.000959	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—CDK4—bone cancer	0.000358	0.00095	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—MET—bone cancer	0.000358	0.00095	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000357	0.000946	CbGpPWpGaD
Rosiglitazone—ALB—Folate Metabolism—TP53—bone cancer	0.000343	0.000909	CbGpPWpGaD
Rosiglitazone—ACSL4—Metabolism—PTGS2—bone cancer	0.000332	0.00088	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NDUFA12—bone cancer	0.000325	0.000862	CbGpPWpGaD
Rosiglitazone—PPARG—Gene Expression—EZH2—bone cancer	0.000325	0.00086	CbGpPWpGaD
Rosiglitazone—PPARG—Circadian rythm related genes—TP53—bone cancer	0.000313	0.000829	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—SPARC—bone cancer	0.000308	0.000815	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—NT5C3A—bone cancer	0.000302	0.000801	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—NT5C3A—bone cancer	0.0003	0.000796	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NDUFA12—bone cancer	0.000299	0.000793	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—MMP2—bone cancer	0.000299	0.000792	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NDUFA12—bone cancer	0.000297	0.000786	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—ENO2—bone cancer	0.000292	0.000775	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—GNA11—bone cancer	0.000281	0.000746	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—DHFR—bone cancer	0.000271	0.000719	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—NT5C3A—bone cancer	0.00027	0.000715	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—IL3—bone cancer	0.000255	0.000676	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NDUFA12—bone cancer	0.000253	0.000672	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—GNA11—bone cancer	0.000253	0.000672	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—NT5C3A—bone cancer	0.000248	0.000657	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—NT5C3A—bone cancer	0.000246	0.000652	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—ENO2—bone cancer	0.00023	0.00061	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—CYP3A4—bone cancer	0.00023	0.000609	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000229	0.000606	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—MMP9—bone cancer	0.000225	0.000595	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—DHFR—bone cancer	0.000214	0.000566	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—NT5C3A—bone cancer	0.00021	0.000557	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—ENO2—bone cancer	0.000205	0.000543	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—GNA11—bone cancer	0.0002	0.000529	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—GSTP1—bone cancer	0.000197	0.000521	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—ENO2—bone cancer	0.000194	0.000513	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—DHFR—bone cancer	0.00019	0.000504	CbGpPWpGaD
Rosiglitazone—PPARG—Developmental Biology—EGFR—bone cancer	0.000181	0.000481	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—CYP3A4—bone cancer	0.000181	0.00048	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.00018	0.000477	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—DHFR—bone cancer	0.00018	0.000476	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—GNA11—bone cancer	0.000178	0.000471	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—GNA11—bone cancer	0.000168	0.000445	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—PLAU—bone cancer	0.000167	0.000443	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—CYP3A4—bone cancer	0.000161	0.000427	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.00016	0.000425	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—GSTP1—bone cancer	0.000155	0.00041	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—CYP3A4—bone cancer	0.000152	0.000404	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—GSTP1—bone cancer	0.000138	0.000365	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—ENO2—bone cancer	0.000132	0.000351	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—ENO2—bone cancer	0.000132	0.000349	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—GSTP1—bone cancer	0.00013	0.000345	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—DHFR—bone cancer	0.000123	0.000325	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—DHFR—bone cancer	0.000122	0.000323	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—ENO2—bone cancer	0.000118	0.000313	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GNA11—bone cancer	0.000115	0.000304	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GNA11—bone cancer	0.000114	0.000302	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—DHFR—bone cancer	0.00011	0.00029	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—ENO2—bone cancer	0.000109	0.000288	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—ENO2—bone cancer	0.000108	0.000285	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—CYP3A4—bone cancer	0.000104	0.000276	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000103	0.000274	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—CYP3A4—bone cancer	0.000103	0.000274	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000103	0.000273	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GNA11—bone cancer	0.000102	0.000271	CbGpPWpGaD
Rosiglitazone—PPARG—Metabolism—PTGS2—bone cancer	0.000102	0.00027	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—DHFR—bone cancer	0.000101	0.000267	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—DHFR—bone cancer	9.99e-05	0.000265	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GNA11—bone cancer	9.42e-05	0.00025	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GNA11—bone cancer	9.34e-05	0.000247	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—CYP3A4—bone cancer	9.28e-05	0.000246	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.23e-05	0.000245	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—ENO2—bone cancer	9.2e-05	0.000244	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—GSTP1—bone cancer	8.89e-05	0.000236	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—GSTP1—bone cancer	8.84e-05	0.000234	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—CYP3A4—bone cancer	8.54e-05	0.000226	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—DHFR—bone cancer	8.54e-05	0.000226	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—CYP3A4—bone cancer	8.46e-05	0.000224	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.42e-05	0.000223	CbGpPWpGaD
Rosiglitazone—SLCO1B1—Metabolism—PTGS2—bone cancer	8.02e-05	0.000213	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GNA11—bone cancer	7.98e-05	0.000211	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—GSTP1—bone cancer	7.94e-05	0.00021	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—GSTP1—bone cancer	7.3e-05	0.000194	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—GSTP1—bone cancer	7.24e-05	0.000192	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—CYP3A4—bone cancer	7.23e-05	0.000192	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.2e-05	0.000191	CbGpPWpGaD
Rosiglitazone—PTGS1—Metabolism—PTGS2—bone cancer	7.13e-05	0.000189	CbGpPWpGaD
Rosiglitazone—CYP2A6—Metabolism—PTGS2—bone cancer	6.75e-05	0.000179	CbGpPWpGaD
Rosiglitazone—ALB—Hemostasis—TP53—bone cancer	6.73e-05	0.000178	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—GSTP1—bone cancer	6.19e-05	0.000164	CbGpPWpGaD
Rosiglitazone—CYP2C8—Metabolism—PTGS2—bone cancer	4.61e-05	0.000122	CbGpPWpGaD
Rosiglitazone—ALB—Metabolism—PTGS2—bone cancer	4.58e-05	0.000121	CbGpPWpGaD
Rosiglitazone—CYP2C19—Metabolism—PTGS2—bone cancer	4.11e-05	0.000109	CbGpPWpGaD
Rosiglitazone—CYP2D6—Metabolism—PTGS2—bone cancer	3.78e-05	0.0001	CbGpPWpGaD
Rosiglitazone—CYP2C9—Metabolism—PTGS2—bone cancer	3.75e-05	9.94e-05	CbGpPWpGaD
Rosiglitazone—CYP1A2—Metabolism—PTGS2—bone cancer	3.2e-05	8.49e-05	CbGpPWpGaD
